Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 6, 1998, Pages 605-614

  Cohen, Michael A ^a   Huband, Michael D ^a   Yoder, Steven L ^a   Gage, Jeffrey W ^a   Roland, Gregory E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 (3 AMINO 1 PYRROLIDINYL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXO 1,8 NAPHTHYRIDINE 3 CARBOXYLIC ACID; ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICE; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; QUINOLONES;

EID: 0031865864     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.6.605     Document Type: Article

References (46)

1. Cohen,M. A., Huband, M. D., Mailloux, G .B., Yoder, S. L., Roland, G. E. & Heifetz, C. L. (1991). In vitro antibacterial activities of the fluoroquinolones PD117596, PD124816, and PD127391. Diagnostic Microbiology and Infectious Disease 14, 245-58.
2. Cohen, M. A., Huband, M. D., Mailloux, G. B., Yoder, S. L., Roland, G. E., Domagala, J. M. et al. (1991). In vitro antibacterial activities of PD131628, a new 1,8-naphthyridine anti-infective agent. Antimicrobial Agents and Chemotherapy 35, 141-6.
3. Dever, L. L., Jorgensen, J. H. & Barbour, A. G. (1992). In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. Journal of Clinical Microbiology 30, 2692-7.
4. MacGowan, A. P., Wootton, M., Hedges, A. J., Bowker, K. E., Holt, H. A. & Reeves, D. S. (1996). A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative β-lactam, amino-glycoside and fluoroquinolone. Journal of Antimicrobial Chemotherapy 38, 193-203.
5. DeWitt, C. W. (1958). Differential effect of hog gastric mucin on properdin and host resistance to infection. Journal of Bacteriology 76, 631-9.
6. Boniece, W. S., Wick, W. E., Holmes, D. H. & Redman, C. E. (1962). In vitro and in vivo laboratory evaluation of cephalothin, a new broad spectrum antibiotic. Journal of Bacteriology 84, 1292-6.
7. Lancefield, R. C. (1933). A serological differentiation of human and other groups of hemolytic streptococci. Journal of Experimental Medicine 57, 571-96.
8. White, H. J., Wadsworth, B. C., Redin, G. S. & Gentile, A. J. (1952). An evaluation of elkosin, gantrisin and sulfacetamide in standardized infection in mice. Antibiotics and Chemotherapy 2, 659-77.
9. Cohen, M. A., Yoder, S. L., Huband, M. D., Roland, G. E. & Courtney, C. L. (1995). In vitro and in vivo activity of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrobial Agents and Chemotherapy 39, 2123-7.
10. Erlandson, A. H., Fisher, M. W., Gagliardi, L. A., Pearson, I. A. & Waisbren, B. A. (1961). Characteristics of strains of Escherichia coli associated with severe infections in adults. Journal of Infectious Diseases 108, 189-94.
11. National Committee for Clinical Laboratory Standards. (1992). Methods for Determining Bactericidal Activity of Antimicrobial Agents - Tentative Guideline M26-T. NCCLS, Villanova, PA.
12. Barry, A. L. (1990). In vitro activity of the quinolones and related compounds. In The New Generation of Quinolones (Siporin, C., Heifetz, C. L. & Domagala, J. M., Eds), pp. 79-105. Marcel Dekker, New York.
13. Wolfson, J. S. & Hooper, D. C. (1989). Fluoroquinolone antimicrobial agents. Clinical Microbiology Reviews 2, 378-424.
14. Anderson, R. & Jooné, G. K. (1993). In vitro investigation of the intraphagocytic bioactivities of ciprofloxacin and the new fluoroquinolone agents, clinafloxacin (CI-960) and PD 131628. Chemotherapy 39, 424-31.
15. Barrett, M. S., Jones, R. N., Erwin, M. E., Johnson, D. M. & Briggs, B. M. (1991). Antimicrobial activity evaluations of two new quinolones, PD 127391 (CI-960 and AM-1091) and PD 131628. Diagnostic Microbiology and Infectious Disease 14, 389-401.
16. Barry, A. L. & Fuchs, P. C. (1991). Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin. European Journal of Clinical Microbiology and Infectious Disease 10, 168-71.
17. Boisivon, A., Dhoyen, N. & Carbon, C. (1995). Activity of CI-960 alone and in combination with amoxycillin against Listeria monocytogenes, and comparison with other quinolones. Journal of Antimicrobial Chemotherapy 36, 527-30.
18. Cherubin, C. E. & Stratton, C. W. (1993). Bactericidal activity of ofloxacin, levofloxacin and other fluoroquinolones compared with agents proven against Listeria monocytogenes. Drugs 45, Suppl. 3, 217-18.
19. Cooper, M. A., Andrews, J. M. & Wise, R. (1992). In-vitro activity of PD 131628, a new quinolone antimicrobial agent. Journal of Antimicrobial Chemotherapy 39, 519-27.
20. Fuchs, P. C., Barry, A. L. & Pfaller, M. A. (1994). Antibacterial activity of PD 131628 and proposed disc diffusion susceptibility test criteria. Journal of Antimicrobial Chemotherapy 33, 1147-54.
21. Kaatz, G. W., Seo, S. M., Lamp, K. C., Bailey, E.M. & Rybak, M. J. (1992). CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Antimicrobial Agents and Chemotherapy 36, 1192-7.
22. Khardori, N., Reuben, A., Rosenbaum, B., Rolston, K. & Bodey, G. P. (1990). In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Antimicrobial Agents and Chemotherapy 34, 1609-10.
23. Khardori, N., Shawar, R., Gupta, R., Rosenbaum, B. & Rolston, K. (1993). In vitro antimicrobial susceptibilities of Nocardia species. Antimicrobial Agents and Chemotherapy 37, 882-4.
24. Neu, H. C., Novelli, A. & Chin, N.-X. (1989). Comparative in vitro activity of a new quinolone, AM-1091. Antimicrobial Agents and Chemotherapy 33, 1036-41.
25. Norrby, S. R. & Jonsson, M. (1988). Comparative in vitro activity of PD 127391, a new fluorinated 4-quinolone derivative. Antimicrobial Agents and Chemotherapy 32, 1278-81.
26. Wise, R., Ashby, J. P. & Andrews, J. M. (1988). In vitro activity of PD 127391, an enhanced-spectrum quinolone. Antimicrobial Agents and Chemotherapy 32, 1251-6.
27. Zabinski, R. A., Walker, K. J., Larsson, A. J., Moody, J. A., Kaatz, G. W. & Rotschafer, J. C. (1995). Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones. Antimicrobial Agents and Chemotherapy 39, 507-12.
28. Ford, A. S., Baltch, A. L., Smith, R. P. & Ritz, W. (1993). Invitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents. Journal of Antimicrobial Chemotherapy 31, 523-32.
29. Morrissey, I. & Smith, J. T. (1990). PD 127391-2: a 4-quinolone bactericidal under anaerobic conditions. In Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990, Abstract 377, p. 149. American Society for Microbiology, Washington, DC.
30. John, J. F., Atkins, L. T., Maple, P. A. H. & Bratoeva, M. (1992). Activities of newer fluoroquinolones against Shigella sonnei. Antimicrobial Agents and Chemotherapy 36, 2346-8.
31. Lewin, C. S. & Amyes, S. G. B. (1990). Bactericidal action of PD 127391, an enhanced spectrum quinolone. Journal of Medical Microbiology 33, 67-70.
32. Lewin, C. S. (1992). Antibacterial activity of a 1,8-naphthyridine quinolone, PD 131628. Journal of Medical Microbiology 36, 353-7.
33. Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. (1996). Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. Journal of Antimicrobial Chemotherapy 37, 77-84.
34. Forstall, G. J., Knapp, C. C. & Washington, J. A. (1994). Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci. Antimicrobial Agents and Chemotherapy 38, 1868-70.
35. Burney, S., Landman, D. & Quale, J. M. (1994). Activity of clinafloxacin against multidrug-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 38, 1668-70.
36. Perri, M. B., Chow, J. W. & Zervos, M. J. (1993). In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci. Diagnostic Microbiology and Infectious Disease 17, 151-5.
37. García-Rodríguez, J. A., Sánchez, J. E. G., Trujillano, I., García Sánchez, E. G., García García, M. I. G. & Fresnadillo, M. J. (1995). Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrobial Agents and Chemotherapy 39, 1194-5.
38. Van Rensburg, C. E. J., Jooné, G. K. & Anderson, R. (1995). An in vitro investigation of the bioactivities of ciprofloxacin and the new fluoroquinolone agents clinafloxacin (CI-960) and PD 131628 against Mycobacterium tuberculosis in human macrophages. Chemotherapy 41, 234-8.
39. Sesnie, J. C., Courtney, C. L., Desaty, T. M., Griffin, T. J., Saby, J. A. & Heifetz, C. L. (1991). In vivo efficacy of PD 127391 (CI-960) in a Pseudomonas aeruginosa mouse renal abscess model. In Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1153, p. 291. American Society for Microbiology, Washington, DC.
40. Kaatz, G. W., Barriere, S. L., Schaberg, D. R. & Fekety, R. (1987). The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. Journal of Antimicrobial Chemotherapy 20, 753-8.
41. Kaatz, G. W., Barriere, S. L., Schaberg, D. R. & Fekety, R. (1987). Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrobial Agents and Chemotherapy 31, 527-30.
42. Cohen, M. A., Gage, J. W., Huband, M. D., Meservey, M. A., Vander Roest, S. R. & Yoder, S. L. (1995). Efficacy of quinolones in preventing Staphylococcus aureus-induced abscess in mice. Journal of Antimicrobial Chemotherapy 36, 551-5.
43. Bron, N. J., Dorr, M. B., Mant, T. G., Webb, C. L & Vassos, A. B. (1996). The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects. Journal of Antimicrobial Chemotherapy 38, 1023-9.
44. Randinitis, E. J. (1997). Personal communication. Pharmacokinetics and Drug Metabolism Department, Parke-Davis Pharmaceutical Research.
45. Lew, D. (1994). Opportunities for i.v. to oral switch in the management of infections: the role of quinolones. International Journal of Antimicrobial Agents 4, Suppl. 2, S53-7.
46. Tack, K. J., McGuire, N. M. & Eiseman, I. A. (1995). Initial clinical experience with clinafloxacin in the treatment of serious infections. Drugs 49, Suppl. 2, 488-91.